New “Medications, Healthcare Equipment and Cosmetics Monthly bill 2022” Can Be Designed Strong
It is heartening that the obsolete Prescription drugs and Cosmetics Act 1940 is getting replaced by the proposed New Medications, Professional medical Products and Cosmetics...
Washington Healthcare Update – March 2023 | McGuireWoods Consulting
This Week in Washington: Workforce issues studied, PBMs under more scrutiny Upcoming Hearings Congress House House Oversight and Accountability Committee Chairman Launches Investigation into Pharmacy...
COVID-19 Vaccination For the duration of Being pregnant Identified to Protect Infants From An infection, Healthcare facility Admission
New analysis has uncovered that 2 doses of mRNA COVID-19 vaccine for the duration of pregnancy are hugely efficient in opposition to infection with the...
Modernization Of Cosmetics Regulation Act Of 2022: What You Need To Know – Healthcare
On December 29, 2022, President Biden signed into law the
 Consolidated Appropriations Act, 2023, which contains the
 Modernization of Cosmetics Regulation Act of 2022 (MoCRA)....
US FDA User Fee Riders Make It Across The Line: A Guide To The Food And Drug Omnibus Reform Act (FDORA) – Healthcare
On December 29, 2022, President Biden signed into law the Consolidated Appropriations Act, 2023, a $1.7 trillion omnibus that will fund the federal government through...
Washington Healthcare Update- Dec 19, 2022
This Week in Washington: All Efforts Are on Funding the Government Through the Rest of the Fiscal Year Congress House Senate Administration Other Activity Proposed...
Digital Health The Internet Of Healthcare Things And Beyond -Biplab Lenin
From a regulator’s point of view, an efficient, risk-based approach to regulating digital health technology will foster innovation of digital health products. Regulators must take...
Senate HELP Committee Unveils Draft FDA User Fee Reauthorization Legislation, With Major Reforms To In Vitro Diagnostics, Cosmetics And Dietary Supplements – Healthcare
On May 17 the Senate Health, Education, Labor and Pensions (HELP) Committee released a bipartisan legislative discussion draft of the Food and Drug Administration (FDA)...
No Surprises Act Challenges, Win For Providers – Food, Drugs, Healthcare, Life Sciences
United States: No Surprises Act Challenges, Win For Providers 22 March 2022 Foley & Lardner To...
Fourth Circuit Adopts Objective Reasonableness Standard In Determining Scienter Element Of The False Claims Act – Food, Drugs, Healthcare, Life Sciences
The Fourth Circuit, in United States ex rel. Sheldon v. Allergan Sales, LLC, No. 20-2330, 2022 WL 211172 (4th Cir. Jan. 25, 2022) recently upheld...